BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment
- PMID: 16055611
- PMCID: PMC1747200
- DOI: 10.1136/thx.2005.046797
BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment
Abstract
Guidelines have been compiled by The Joint Tuberculosis Committee of the British Thoracic Society to quantify the risks of reactivation of tuberculosis with anti-tumour necrosis factor alpha (anti-TNF-alpha) treatment. These guidelines are intended to inform respiratory physicians, gastroenterologists, rheumatologists and dermatologists, together with specialist nurses in those disciplines.
Similar articles
-
Assessing risk and managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNFalpha treatment.Cytokine. 2004 Nov 21-Dec 7;28(4-5):179-81. doi: 10.1016/j.cyto.2004.07.013. Cytokine. 2004. PMID: 15588693
-
British Thoracic Society (BTS) recommendations for assessing risk and managing tuberculosis in patients due to start anti-TNF-{alpha} treatments.Rheumatology (Oxford). 2005 Oct;44(10):1205-6. doi: 10.1093/rheumatology/kei103. Rheumatology (Oxford). 2005. PMID: 16172152 No abstract available.
-
From the Centers for Disease Control and Prevention. Update: Fatal and severe liver injuries associated with Rifampin and Pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations--United States, 2001.JAMA. 2001 Sep 26;286(12):1445-6. JAMA. 2001. PMID: 11596606 No abstract available.
-
Considering the role of four months of rifampin in the treatment of latent tuberculosis infection.Am J Respir Crit Care Med. 2004 Oct 15;170(8):832-5. doi: 10.1164/rccm.200405-584PP. Epub 2004 Aug 5. Am J Respir Crit Care Med. 2004. PMID: 15297274 Review. No abstract available.
-
Rifampin and pyrazinamide for treatment of latent tuberculosis infection: is it safe?Am J Respir Crit Care Med. 2003 Mar 15;167(6):809-10. doi: 10.1164/rccm.2301002. Am J Respir Crit Care Med. 2003. PMID: 12623855 Review. No abstract available.
Cited by
-
Choosing Therapy for Moderate to Severe Crohn's Disease.J Can Assoc Gastroenterol. 2023 Sep 22;7(1):1-8. doi: 10.1093/jcag/gwad023. eCollection 2024 Feb. J Can Assoc Gastroenterol. 2023. PMID: 38314180 Free PMC article.
-
Clinical use of anti-TNF therapy and increased risk of infections.Drug Healthc Patient Saf. 2013;5:79-99. doi: 10.2147/DHPS.S28801. Epub 2013 Mar 28. Drug Healthc Patient Saf. 2013. PMID: 23569399 Free PMC article.
-
Single-centre experience of granulomatous interstitial nephritis-time for a new approach?Clin Kidney J. 2017 Apr;10(2):249-254. doi: 10.1093/ckj/sfw119. Epub 2017 Jan 7. Clin Kidney J. 2017. PMID: 28396742 Free PMC article.
-
Active Tuberculosis Incidence and Characteristics in Patients Treated with Tumor Necrosis Factor Antagonists According to Latent Tuberculosis Infection.Sci Rep. 2017 Jul 25;7(1):6473. doi: 10.1038/s41598-017-06899-1. Sci Rep. 2017. PMID: 28743918 Free PMC article.
-
QuantiFERON-TB Gold In-Tube assay for screening arthritis patients for latent tuberculosis infection before starting anti-tumor necrosis factor treatment.PLoS One. 2015 Mar 6;10(3):e0119260. doi: 10.1371/journal.pone.0119260. eCollection 2015. PLoS One. 2015. PMID: 25746854 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical